30% PAT Growth Masks Sequential Softness and Co-Lending Stall

Paisalo reported 30% PAT growth and record ₹173 Cr in quarterly disbursements — metrics that on their own read as a triumph. But the company's own sequential numbers tell a different story: profit fell 15.1% quarter-on-quarter, revenue was essentially flat, and collection efficiency slipped 1% even as the loan book raced ahead. This is not a slowdown, management insists — it is a timing lag as raised capital deploys into loans. Whether that explanation holds, and more pressingly, whether co-lending delays are truly transient, will define the next two quarters.

Year-on-year, Paisalo's story is unambiguously strong. PAT growth of 30%, AUM expansion of 28%, and disbursement momentum of 128% validate the four-pillar strategy (distribution expansion, product diversification, AI scaling, liability optimization). The 5,995-touch-point network across 23 states has broadened reach, six new product lines have opened addressable market, and 18 AI bots now handle 2 million customer calls daily. Net and gross NPA remain exceptional at 0.49% and 0.70% respectively, despite the loan book scaling at pace. On these metrics, Paisalo's execution is hard to fault.

But zoom to the quarter itself — Q1 FY27 vs Q4 FY26 — and the picture inverts. Revenue flatlined at ₹260.3 Cr (down 0.2% QoQ), and PAT contracted from ₹72.3 Cr to ₹61.3 Cr, a 15.1% quarter-on-quarter drop. Interest expense jumped 32% QoQ to ₹115 Cr while operating costs fell 32% to ₹46 Cr — the classic signature of capital raised but not yet deployed. Management attributes the gap to a standard lending-cycle lag: funds issued late in Q4 flow into loan disbursements in Q2-Q3, creating a Q1 income trough. "Generally there is a lag between the debt issuance and conversion of funds into loan books. Hence there is always a transient impact in Q1," Deputy MD Santanu Agarwal explained. If true, Q2 should show recovery. If not, the quarter raises questions about capital deployment efficiency at a company targeting a 3-year doubling of profit.

The market's response has been remarkably muted. The day-1 decline of 0.23% held, and a day-3 pop of 1.16% suggests institutional comfort with the print — but no enthusiasm. Ownership data reveals the real verdict: FII investors sold heavily, trimming their stake from 17.54% (Q3 FY26) to 6.79% (Q1 FY27), a dramatic 10.75 percentage-point exodus in just two quarters. Domestic institutional interest flatlined (DII unchanged at 6.83%). Meanwhile, promoters have been accumulating aggressively, buying an additional 5% to reach 46.72% of the company — a strong signal of internal conviction, and one that typically precedes a re-rating when execution clears near-term hurdles. The stock trades at ₹69.94, down 9.63% from its all-time high but up 133% from the 52-week low. It sits above its 50-day and 200-day simple moving averages but below the 20-day, suggesting consolidation near medium-term resistance. RSI at 40.8 indicates neutral momentum — neither overbought nor oversold, but stalled. Volume is normal, not a sign of forced selling or frenzied buying. This is a stock the market has decided to pause on, awaiting clarity on two things: whether Q2 shows sequential PAT recovery (validating the fund-lag explanation), and whether the SBI co-lending timeline clarifies (resolving a material growth uncertainty).